We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 2,657

Challenges for Protecting Genetic Patents
  • Watermark Intellectual Property
  • USA, Australia
  • November 16 2018

Decades of advances in sequencing technology have led to breakthroughs in not just the sensitivity of DNA tests, but also the speed and costs


Sigma Pharmaceuticals Case Clarifies Aspects of Compensable Loss
  • Spruson & Ferguson
  • Australia
  • November 13 2018

The recent decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth 2018 FCA 1556 has clarified, among other things, a number of issues


Global Deregulation in Cannabinoid Market Sparks Flurry of Innovation From Dynamic Startups
  • Clarivate Analytics
  • USA, Australia, Canada, Global
  • November 8 2018

Analysis of Derwent patent data conducted by Clarivate Analytics indicates startups in the US, Canada, and Australia are the market leaders in the


Quite an undertaking: Quantifying damages from an interlocutory injunction preventing sale of a generic pharmaceutical
  • Clayton Utz
  • Australia
  • November 8 2018

Claimants seeking to rely on the undertakings as to damages in patent cases of this kind must be in a position to prove, on the balance of


Computer Software Inventions Patentability Case Has Got IPTA’s Patents in a Bunch
  • Macpherson Kelley
  • Australia
  • November 7 2018

A high profile appeal to the Full Court of the Federal Court of Australia about the patentability of computer inventions could reset the bar on the


NSW Government Bulletin - 31 October 2018
  • Holding Redlich
  • Australia
  • October 31 2018

On 24 October 2018 the NSW Government introduced the Justice Legislation Amendment Bill (No 3) 2018 (the Bill). The Bill contains a range of


Is the tide about to turn for pharmaceutical patentees in Australia?
  • Griffith Hack
  • Australia
  • October 31 2018

Pharmaceutical patentees have an enviable record of succeeding in contested applications for interlocutory (preliminary or interim) injunctions


Ignorance is bliss for the patentee, but best method may be a problem for other divisional applications
  • Davies Collison Cave
  • Australia
  • October 29 2018

In what is becoming a series of articles (see here and here), we bring another tale of the hazards of Australia’s requirement to disclose the best


Australian firms play smart with limited patent resources
  • IAM
  • Australia
  • October 26 2018

IPBC Australasia found its host country close to the finish line in an IP system reform effort that has gone on for several years now. Questions over


The future of software patents in Australia
  • Watermark Intellectual Property
  • Australia
  • October 25 2018

The Institute of Patent and Trade Mark Attorneys of Australia (IPTA), the representative body for Australian patent attorneys, has filed an